News from Friday, March 14, 2025
Articles
Value Viewpoint: March 14, 2025
(3/14, Kimberly Westrich, LinkedIn) comments “New research published in PharmacoEconomics reviews the tools and methods currently used for addressing heterogeneity in economic evaluations, examines the extent to which heterogeneity has been addressed in U.S. economic evaluations to date, and explains why it matters.” Full
Lasmiditan Shows Promise for Menstrual Migraine, Requires Further Safety Research
(3/14, Rajan Saha, Clinical Pain Advisor) reports “Lasmiditan is a promising treatment for menstrual migraine, offering sustained pain relief comparable to or exceeding that of triptans. However, further research is needed to fully assess its safety profile. These study results were published in Pain Therapy.” Full
Journals
Lasmiditan and Different Triptans in Menstrual Migraine: A Bayesian Network Meta-Analysis
Zhaoming Song, et al.
February 24, 2025, Pain and Therapy
Exploring the Outcomes and Endpoints Used in Gastrointestinal Research in Cystic Fibrosis: A Systematic Review
Rebecca Jane Calthorpe, et al.
March 13, 2025, medRxiv
Patient Experiences with the Impacts of Multiple Sclerosis & Disease-Modifying Therapies
Talente, et al.
March 15, 2025, ClinicoEconomics and Outcomes Research
ClinicoEconomics and Outcomes Research
Two-Arm Crossover Randomized Controlled Trial Versus Meta-Analysis of N-of-1 Studies: Comparison of Statistical Efficiency in Determining an Intervention Effect
Anna Eleonora Carrozzo, et al.
April 2025, Biometrical Journal